Back to Search
Start Over
Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial.
- Source :
- Metabolism: Clinical & Experimental; Sep2017, Vol. 74, p43-46, 4p
- Publication Year :
- 2017
- Subjects :
- PROPROTEIN convertases
SUBTILISINS
INTERNAL medicine
MEDICAL schools
METABOLISM
Subjects
Details
- Language :
- English
- ISSN :
- 00260495
- Volume :
- 74
- Database :
- Supplemental Index
- Journal :
- Metabolism: Clinical & Experimental
- Publication Type :
- Academic Journal
- Accession number :
- 124382496
- Full Text :
- https://doi.org/10.1016/j.metabol.2017.04.007